This study’s publication comes as hundreds of people pursue Risperdal lawsuits for gynecomastia and other serious side effect allegedly associated with its use.
New York, New York (PRWEB) January 13, 2015
As Risperdal lawsuits (http://www.risperdallawsuit2014.com/) continue to move forward in U.S. courts, Bernstein Liebhard LLP notes the publication of a new study suggesting that elderly people treated with atypical antipsychotics may be at risk for certain serious side effects. According to a report from DailyRX News, the research looked at 200,000 older adults who had been prescribed an oral atypical antipsychotic, including Risperdal, Zyprexa or Seroquel, for dementia or behavioral disorders.*
The authors of the report concluded that patients who had a new prescription for an atypical antipsychotic drug faced a 52 percent increased risk of a serious fall, as well as a 50 percent increased risk of a bone fracture. They asserted that their findings call into question the widespread off-label use of Risperdal and other atypical antipsychotic medications to treat dementia and curb behavioral issues in elderly people.*
“This study’s publication comes as hundreds of people pursue Risperdal lawsuits for gynecomastia and other serious side effect allegedly associated with its use, and that also take issue with off-label use of the drug. This research just confirms that medications like Risperdal can be associated with some significant risks,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently representing numerous Risperdal lawsuit plaintiffs who allegedly developed gynecomastia (male breast growth) as a result of this medication, and continues to offer free legal consultations to men and boys who allegedly experienced excessive breast growth due to Risperdal.
Court records indicate more than 1,200 Risperdal lawsuits are now pending in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing gynecomastia claims. Among other things, plaintiffs allege Johnson & Johnson and its Janssen Pharmaceuticals unit improperly marketed Risperdal for off-label uses, including as a treatment for elderly dementia patients. The Risperdal gynecomastia cases pending in the proceeding further allege that the companies failed to warn patients about the drug’s potential to stimulate the body’s production of prolactin, a hormone tied to female breast development that can also cause excessive breast growth in men. (In Re: Risperdal Litigation, Case Number 100300296).
Johnson & Johnson and Janssen’s marketing of Risperdal has also been called into question on other fronts. In November 2013, for example, the companies reached an accord with the U.S. Department of Justice to pay $2.2 billion to several criminal and civil charges regarding the marketing of several medications, including Risperdal. While Johnson & Johnson and Janssen did plead guilty to promoting Risperdal for off-label use in elderly dementia patients, court records indicate that they did not admit wrongdoing in resolving any of the other allegations, including claims that they had marketed Risperdal for off-label pediatric indications. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Risperdal patients who developed gynecomastia allegedly due to its use may be entitled to file their own lawsuit against Johnson & Johnson and Janssen. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
*dailyrx.com/atypical-antipsychotic-medications-may-pose-increased-risk-falls-and-fractures-elderly, daily RX New, January 12, 2015
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com